Elevation Oncology (NASDAQ:ELEV) Cut to Market Perform at Leerink Partners
Leerink Partners cut shares of Elevation Oncology (NASDAQ:ELEV – Free Report) from an outperform rating to a market perform rating in a research report report published on Friday, Marketbeat Ratings reports. The firm currently has $1.00 price target on the stock, down from their prior price target of $9.00. A number of other analysts have […]
Leerink Partners cut shares of Elevation Oncology (NASDAQ:ELEV – Free Report) from an outperform rating to a market perform rating in a research report report published on Friday, Marketbeat Ratings reports. The firm currently has $1.00 price target on the stock, down from their prior price target of $9.00. A number of other analysts have […]
